^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HER-2/neu peptide vaccine

    i
    Other names: HER-2/neu peptide vaccine, HER-2-neu peptide vaccine, HER-2/neu helper-peptide vaccine
    Associations

    News

    Trials
    Company:
    National Cancer Institute - Bethesda
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    12ms
    VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=43, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> May 2023
    Trial completion • Trial completion date
    |
    HLA-A2 positive
    |
    HER-2/neu peptide vaccine • Leukine (sargramostim) • NeuVax (nelipepimut-S)
    over1year
    Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab (clinicaltrials.gov)
    P1/2, N=22, Completed, University of Washington | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • IFNG (Interferon, gamma)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 expression • HLA-A2 positive
    |
    Herceptin (trastuzumab) • HER-2/neu peptide vaccine
    over1year
    VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, National Cancer Institute (NCI) | N=13 --> 43
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression • HLA-A2 positive
    |
    HER-2/neu peptide vaccine • Leukine (sargramostim) • NeuVax (nelipepimut-S)
    almost2years
    Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab (clinicaltrials.gov)
    P1/2, N=22, Active, not recruiting, University of Washington | Trial completion date: Sep 2023 --> May 2023
    Preclinical • Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • IFNG (Interferon, gamma)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 expression • HLA-A2 positive
    |
    Herceptin (trastuzumab) • HER-2/neu peptide vaccine
    4years
    Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab (clinicaltrials.gov)
    P1/2, N=26, Active, not recruiting, University of Washington | Trial completion date: Sep 2020 --> Sep 2023 | Trial primary completion date: Sep 2020 --> Mar 2021
    Clinical • Preclinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • HER-2/neu peptide vaccine
    over4years
    Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab (clinicaltrials.gov)
    P1/2, N=26, Active, not recruiting, University of Washington | Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Mar 2020 --> Sep 2020
    Clinical • Preclinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • HER-2/neu peptide vaccine
    almost5years
    Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer (clinicaltrials.gov)
    P1/2, N=50, Completed, University of Washington | Active, not recruiting --> Completed
    Clinical • Trial completion • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HER-2 amplification
    |
    Ampligen (rintatolimod) • HER-2/neu peptide vaccine • Leukine (sargramostim)